[{"address1": "11 Great Valley Parkway", "city": "Malvern", "state": "PA", "zip": "19355", "country": "United States", "phone": "484 328 4701", "website": "https://www.ocugen.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.", "fullTimeEmployees": 65, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shankar  Musunuri M.B.A., Ph.D.", "age": 59, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 1201460, "exercisedValue": 1257295, "unexercisedValue": 263200}, {"maxAge": 1, "name": "Dr. Uday B. Kompella Ph.D.", "age": 56, "title": "Co-founder & Independent Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 56724, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arun  Upadhyay Ph.D.", "age": 40, "title": "Chief Scientific Officer and Head of Research & Development", "yearBorn": 1983, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "John  Kouch J.D.", "title": "General Counsel", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Shine M.B.A.", "title": "Senior Vice President of Commercial", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.32, "open": 1.36, "dayLow": 1.32, "dayHigh": 1.42, "regularMarketPreviousClose": 1.32, "regularMarketOpen": 1.36, "regularMarketDayLow": 1.32, "regularMarketDayHigh": 1.42, "beta": 3.743, "forwardPE": -5.115385, "volume": 4732312, "regularMarketVolume": 4732312, "averageVolume": 9742556, "averageVolume10days": 6325040, "averageDailyVolume10Day": 6325040, "bid": 1.31, "ask": 1.34, "bidSize": 5100, "askSize": 3300, "marketCap": 342246240, "fiftyTwoWeekLow": 0.345, "fiftyTwoWeekHigh": 2.105, "priceToSalesTrailing12Months": 56.700836, "fiftyDayAverage": 1.29782, "twoHundredDayAverage": 0.682575, "currency": "USD", "enterpriseValue": 309722592, "floatShares": 253200340, "sharesOutstanding": 257328000, "sharesShort": 45232214, "sharesShortPriorMonth": 35396705, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.1758, "heldPercentInsiders": 0.014479999, "heldPercentInstitutions": 0.10339, "shortRatio": 3.22, "shortPercentOfFloat": 0.22770001, "bookValue": 0.158, "priceToBook": 8.417722, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -63078000, "trailingEps": -0.26, "forwardEps": -0.26, "lastSplitFactor": "1:60", "lastSplitDate": 1569801600, "enterpriseToRevenue": 51.313, "enterpriseToEbitda": -4.778, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "OCGN", "underlyingSymbol": "OCGN", "shortName": "Ocugen, Inc.", "longName": "Ocugen, Inc.", "firstTradeDateEpochUtc": 1417617000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "169c2c50-f570-39a4-b709-68c305b79bbd", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.33, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.67, "targetMedianPrice": 5.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 39462000, "totalCashPerShare": 0.153, "ebitda": -64827000, "totalDebt": 6941000, "quickRatio": 2.309, "currentRatio": 2.515, "totalRevenue": 6036000, "debtToEquity": 17.111, "revenuePerShare": 0.025, "returnOnAssets": -0.473, "returnOnEquity": -1.10137, "freeCashflow": -48980876, "operatingCashflow": -62054000, "revenueGrowth": 1.426, "operatingMargins": -1.4286, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]